Steroid 5-alpha reductase type II V89L substitution is not associated with risk of prostate cancer in a multiethnic population study.

Abstract

Although the genetic causes of prostate cancer are poorly understood, variation in androgen biosynthesis and metabolism genes has been hypothesized to alter prostate cancer risk [(1)][1] . Steroid 5-α reductase type II , which encodes the enzyme responsible for converting testosterone to